Private equity’s deepening role in US healthcare — from hospitals and nursing homes to high-margin specialty practices — has drawn sharp scrutiny from federal and state enforcers. The Biden-era FTC and DOJ aggressively challenged “roll-up” strategies, warning they can hike prices, reduce care quality, and limit access. While the second Trump administration appears less hostile, state regulators have stepped up, using “mini-HSR” laws in at least 15 states to review even smaller healthcare deals.
Why US regulators are cracking down on private equity investments in the healthcare sector (Global Competition Review)
0